ClinicalTrials.gg
RecruitingNCT07419997TRAILBLAZERUpdated Feb 19, 2026

A Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke

An observational study in Stroke, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's title name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Xuanwu Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing — 30 open to participants now, 31 under way, 2 of them phase 3. Ischemic Stroke · Xuanwu Hospital, Beijing.

Planned enrollment
3rd of 24
2,600 · median 350
Started
2025
with 10 others
Observational
24 of 52
15 open now
Primary completion
2026-12
later than 9 of 30 live
Registered
45th of 52
by date

Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 3rd largest by planned enrollment of the 24 observational ones that give a count, is one of 11 that started in 2025, is one of 24 observational ones, reaches primary completion later than 9 of the 30 other live ones, and was the 45th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

30 of the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

A multicenter, retrospective, observational cohort study on intravenous thrombolysis beyond the time window for acute ischemic stroke

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Acute ischemic stroke
  • Alteplase
  • Tenecteplase
  • Stroke at 4.5 to 24 Hours
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 2,600 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

According to the survey, each center has at least 100 cases of thrombolysis with alteplase or tenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours each year. Data will be collected for 5 years, and it is estimated that a total of no less than 2,000 cases will be included.

Eligibility criteria

  1. Patients with acute ischemic stroke, regardless of gender;
  2. Age ≥ 18 years old;
  3. Time from onset to treatment within 4.5 - 24 hours (the onset time refers to the last time when they appeared normal);
  4. Complete relevant clinical data (including gender, age, mRS, NIHSS, etc.).
06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Alteplase group

    The research participants received Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours

  • Tenecteplase group

    The research participants received Tenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours

07

What researchers measure

Primary outcomes

  1. Proportion of study participants with mRS scores of 0 - 1

    Proportion of study participants with mRS scores of 0 - 1

    Time frame: at 90 (±7) days

Secondary outcomes

  1. Distribution of mRS scores ranging from 0 to 6

    Distribution of mRS scores ranging from 0 to 6

    Time frame: at 90 (±7) days

  2. Proportion of study participants with mRS scores of 0 - 2

    Proportion of study participants with mRS scores of 0 - 2

    Time frame: at 90 (±7) days

  3. The proportion of study participants with a NIHSS score of ≤1 or a decrease of ≥8 points compared to the baseline

    The proportion of study participants with a NIHSS score of ≤1 or a decrease of ≥8 points compared to the baseline

    Time frame: at 24 (±12) hours

  4. mortality rate

    mortality rate

    Time frame: at 90 (±7) days

  5. Symptomatic intracranial hemorrhage

    Symptomatic intracranial hemorrhage

    Time frame: within 36 hours

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Dec 29, 2025
Primary completionEst.
Dec 29, 2026
CompletionEst.
Dec 29, 2026
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07419997
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Dec 29, 2025
Primary completion
Dec 29, 2026 (estimated)
Completion
Dec 29, 2026 (estimated)
Last update
Feb 19, 2026

Study contacts

Xin Xing, MD
Contact
drxingxin@126.com
01083198082

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion